LEADER 01365nam  2200397   450 
001 9910704817703321
005 20131021151307.0
035   $a(CKB)5470000002445562
035   $a(OCoLC)861189587
035   $a(EXLCZ)995470000002445562
100   $a20131021d2013      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aMedicare $ehigher use of costly prostate cancer treatment by providers who self-refer warrants scrutiny : report to congressional requesters
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2013.
215   $a1 online resource (iii, 44 pages) $ccolor illustrations
300   $aTitle from title screen (viewed Oct. 17, 2013).
300   $a"July 2013."
300   $a"GAO-13-525."
320   $aIncludes bibliographical references.
517   $aMedicare 
606   $aMedicare$xEconomic aspects
606   $aProstate$xCancer$xTreatment$xEconomic aspects$zUnited States
606   $aMedicare fraud$xPrevention
615  0$aMedicare$xEconomic aspects.
615  0$aProstate$xCancer$xTreatment$xEconomic aspects
615  0$aMedicare fraud$xPrevention.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910704817703321
996   $aMedicare$92879855
997   $aUNINA